Piperazines

Results: 2894



#Item
901IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA UNITED STATES OF AMERICA  :

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA UNITED STATES OF AMERICA :

Add to Reading List

Source URL: psychrights.org

Language: English - Date: 2009-01-16 12:43:54
902PRODUCT MONOGRAPH  Pr ABILIFY*

PRODUCT MONOGRAPH Pr ABILIFY*

Add to Reading List

Source URL: www.bmscanada.ca

Language: English - Date: 2013-06-06 08:54:21
903Xolegel (ketoconazole) gel label

Xolegel (ketoconazole) gel label

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2010-12-07 10:11:50
904Updated Summary of Product Characteristics pending European Medicine Agency final validation

Updated Summary of Product Characteristics pending European Medicine Agency final validation

Add to Reading List

Source URL: www.servier.com

Language: English - Date: 2014-01-29 08:20:31
905Safety of Flibanserin  for the Treatment of HSDD in  Pre-menopausal Women

Safety of Flibanserin for the Treatment of HSDD in Pre-menopausal Women

Add to Reading List

Source URL: www.fda.gov

Language: English
906Better Treatment Adherence and Lower Health Costs for Cancer Patients Using Nilotinib

Better Treatment Adherence and Lower Health Costs for Cancer Patients Using Nilotinib

Add to Reading List

Source URL: www.analysisgroup.com

Language: English - Date: 2010-12-08 17:42:28
907

PDF Document

Add to Reading List

Source URL: psychrights.org

Language: English - Date: 2007-01-13 22:23:49
908FDA Briefing Document Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee (ODAC) November 5, 2013 DISCLAIMER STATEMENT The attached package contains background information prepared by the Food and D

FDA Briefing Document Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee (ODAC) November 5, 2013 DISCLAIMER STATEMENT The attached package contains background information prepared by the Food and D

Add to Reading List

Source URL: www.fda.gov

Language: English
90911. Drug monitoring and adverse events Friday, 31 October 2014, 12:45-14:15 Chairs: Siva Danaviah (South Africa), Ivan Solovic (Slovakia) Section: Tuberculosis

11. Drug monitoring and adverse events Friday, 31 October 2014, 12:45-14:15 Chairs: Siva Danaviah (South Africa), Ivan Solovic (Slovakia) Section: Tuberculosis

Add to Reading List

Source URL: barcelona.worldlunghealth.org

Language: English - Date: 2014-08-22 04:51:45
910PRODUCT MONOGRAPH  MEGACE* OS (megestrol acetate) Oral Suspension USP, 40 mg/mL Antianorexic / Anticachectic

PRODUCT MONOGRAPH MEGACE* OS (megestrol acetate) Oral Suspension USP, 40 mg/mL Antianorexic / Anticachectic

Add to Reading List

Source URL: www.bmscanada.ca

Language: English - Date: 2014-11-26 15:00:11